Login to Your Account



FDA Panel Set To Hear Cases From Genzyme, TKT, BioMarin

By Kim Coghill


Monday, January 13, 2003
Anyone with an interest in lysosomal storage diseases is certain to focus this week on Bethesda, Md., where the FDA's Endocrinologic and Metabolic Drugs Advisory Committee will review applications from two companies that have a long history of competing with each another. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription